Tresiba (Novo Nordisk) superior to Lantus in lowering hypoglycaemia in Type 2 Diabetes patients

New data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) show that patients with Type 2 Diabetes starting insulin therapy had a 43% lower rate of night-time hypoglycaemia when using Tresiba ( insulin degludec) from Novo Nordisk, compared with those using insulin glargine (0.27 [insulin degludec] versus 0.46 [insulin glargine] episodes per patient per year, p<0.001) with equivalent improvements in glucose control. seerodbard hw et al. reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes. poster presented at the european association of the study of diabetes easd 48th annual meeting october 2012.>